Diffuse Large B-Cell Lymphoma (DLBCL) clinical trials
Showing 101–150 of 175 active trials. Describe your situation to see which ones look like a fit.
- CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
- Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
- Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
- Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
- A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
- A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Evaluate the Safety and Clinical Activity of HH2853
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- Auto Stem Cell Transplant for Lymphoma Patients
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Outpatient Epcoritamab as 2L in NTE R/R DLBCL
- Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
- Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
- Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
- A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- The CARDIOPROTECT Trial
- A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
- A Pilot Study for Pupillary Assessment to Predict CAR-T Related Neurotoxicity
- Study of CAR-T Therapy in Older Patients
- A Study of ARC-02 in B-cell NHL
- A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma
- Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
- Long-term Follow-up Study of Patients Receiving CAR-T Cells
- ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
- Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
- A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
- This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy
- Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
- Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
- MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.